We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-9.11%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.68B
AUM Growth
-$184M
Cap. Flow
+$113M
Cap. Flow %
6.73%
Top 10 Hldgs %
74.63%
Holding
34
New
9
Increased
4
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$72.6M
2
TVTX icon
Travere Therapeutics
TVTX
+$65.9M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$33M
4
SLDB icon
Solid Biosciences
SLDB
+$14.2M
5
KOD icon
Kodiak Sciences
KOD
+$13.4M

Top Sells

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$67.4M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$28.3M
3
AXSM icon
Axsome Therapeutics
AXSM
+$17.4M
4
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$14.8M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$5.06M

Sector Composition

Rank Sector Weight
1 Healthcare 97.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$398M 23.72%
4,132,442
– –
WVE icon
2
Wave Life Sciences
WVE
$1.12B
$160M 9.51%
7,775,207
– –
THOR
3
DELISTED
Synthorx, Inc. Common Stock
THOR
$158M 9.43%
9,724,598
– –
RARX
4
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$115M 6.85%
4,858,260
– –
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$90.5M 5.39%
2,260,751
-1,461,753
-39% -$67.4M
EIDX
6
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$77.8M 4.63%
2,162,671
– –
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.31B
$73.9M 4.4%
3,422,312
+1,537,530
+82% +$33M
STSA
8
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$70.3M 4.19%
+4,681,858
New +$72.6M
ORTX
9
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$62.1M 3.7%
522,448
+11,615
+2% +$1.62M
SLDB icon
10
Solid Biosciences
SLDB
$792M
$47.3M 2.82%
304,744
+125,448
+70% +$14.2M
TVTX icon
11
Travere Therapeutics
TVTX
$5.17B
$46.2M 2.75%
+3,987,560
New +$65.9M
PRVL
12
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$41.3M 2.46%
3,363,605
+619,980
+23% +$7.03M
TGTX icon
13
TG Therapeutics
TGTX
$8.19B
$38.6M 2.3%
6,880,323
– –
ARVN icon
14
Arvinas
ARVN
$530M
$35.8M 2.14%
1,663,512
-24,900
-1% -$611K
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$35.3M 2.1%
2,456,669
– –
MYOV
16
DELISTED
Myovant Sciences Ltd.
MYOV
$32.1M 1.91%
6,166,875
-378,767
-6% -$2.81M
CRNX icon
17
Crinetics Pharmaceuticals
CRNX
$8.88B
$28.2M 1.68%
1,875,209
– –
STOK icon
18
Stoke Therapeutics
STOK
$1.84B
$24.1M 1.43%
1,119,963
– –
SCPH
19
DELISTED
scPharmaceuticals
SCPH
$19.1M 1.14%
3,247,005
– –
KALA icon
20
KALA BIO
KALA
$12.5M
$17.3M 1.03%
1,817
– –
DTIL icon
21
Precision BioSciences
DTIL
$178M
$15.5M 0.92%
61,412
– –
KOD icon
22
Kodiak Sciences
KOD
$2.5B
$14.7M 0.88%
+1,025,165
New +$13.4M
ALEC icon
23
Alector
ALEC
$169M
$14.4M 0.86%
1,000,000
– –
AXSM icon
24
Axsome Therapeutics
AXSM
$11.7B
$13.4M 0.8%
664,385
-676,443
-50% -$17.4M
PTLA
25
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$11.5M 0.69%
+429,399
New +$12.1M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, RA Capital Management held 34 positions worth $1.68B, down 9.9% from $1.86B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

RA Capital Management deployed $113M of net new capital in Q3 2019, opening 9 new positions and adding to 4 existing holdings. Its largest new stake was Satsuma Pharmaceuticals, Inc. Common Stock: 4,681,858 shares worth $70.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Zogenix, Inc., an estimated $67.4M trimmed.

  • RA Capital Management's largest Q3 2019 buy was Satsuma Pharmaceuticals, Inc. Common Stock: 4,681,858 shares worth $70.3M.
  • RA Capital Management added most to Rhythm Pharmaceuticals in Q3 2019, an estimated $33M increase.
  • RA Capital Management's biggest Q3 2019 reduction was Zogenix, Inc., cutting an estimated $67.4M.
  • RA Capital Management fully exited Shockwave Medical, Inc. Common Stock in Q3 2019, selling an estimated $28.3M.
  • RA Capital Management's ten largest holdings make up 75% of its $1.68B portfolio in Q3 2019.
  • RA Capital Management opened 9 new positions and closed 2 in Q3 2019.
  • RA Capital Management's portfolio value fell 9.9% quarter-over-quarter to $1.68B.

Based on RA Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.